Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,842 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.
Fernandez-Martos C, Brown G, Estevan R, Salud A, Montagut C, Maurel J, Safont MJ, Aparicio J, Feliu J, Vera R, Alonso V, Gallego J, Martin M, Pera M, Sierra E, Serra J, Delgado S, Roig JV, Santos J, Pericay C. Fernandez-Martos C, et al. Among authors: martin m. Oncologist. 2014 Oct;19(10):1042-3. doi: 10.1634/theoncologist.2014-0233. Epub 2014 Sep 10. Oncologist. 2014. PMID: 25209376 Free PMC article. Clinical Trial.
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Aparicio J, García-Mora C, Martín M, Petriz ML, Feliu J, Sánchez-Santos ME, Ayuso JR, Fuster D, Conill C, Maurel J. Aparicio J, et al. Among authors: martin m. PLoS One. 2014 Jan 9;9(1):e82209. doi: 10.1371/journal.pone.0082209. eCollection 2014. PLoS One. 2014. PMID: 24416138 Free PMC article. Clinical Trial.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E; Spanish Cooperative Group of Treatment of Digestive Tumors (TTD). Irigoyen A, et al. Among authors: martin m. Eur J Cancer. 2017 Apr;75:73-82. doi: 10.1016/j.ejca.2016.12.032. Epub 2017 Mar 7. Eur J Cancer. 2017. PMID: 28222309 Clinical Trial.
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.
Feliu J, Salud A, Escudero P, López-Gómez L, Pericay C, Castañón C, de Tejada MR, Rodríguez-García JM, Martínez MP, Martín MS, Sánchez JJ, Barón MG; Oncopaz Cooperative Group and Associated Hospitals. Feliu J, et al. Among authors: martin ms. Br J Cancer. 2004 Apr 19;90(8):1502-7. doi: 10.1038/sj.bjc.6601713. Br J Cancer. 2004. PMID: 15083176 Free PMC article. Clinical Trial.
Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.
Laquente B, Macarulla T, Bugés C, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Verdaguer H, Mut A, Vilanova D, García A. Laquente B, et al. Among authors: martin m, martin t. BMC Palliat Care. 2020 Jul 10;19(1):103. doi: 10.1186/s12904-020-00610-4. BMC Palliat Care. 2020. PMID: 32650765 Free PMC article.
Functional characterization of novel compound heterozygous missense SLC5A5 gene variants causing congenital dyshormonogenic hypothyroidism.
Carro GH, Martín M, Savy S, Peyret V, Geysels RC, Montes FA, Bernal Barquero CE, Ricci V, Masnata ME, Masini-Repiso AM, Papendieck P, Tellechea ML, Chiesa AE, Nicola JP. Carro GH, et al. Among authors: martin m. Front Endocrinol (Lausanne). 2024 Dec 19;15:1465176. doi: 10.3389/fendo.2024.1465176. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39749016 Free PMC article.
EZH2 deletion does not impact acinar regeneration but restricts progression to pancreatic cancer in mice.
Jaune-Pons E, Wang X, Mousavi F, Klassen Z, Elkaoutari A, Berger K, Johnson C, Martin MB, Aggarwal S, Brar S, Khalid M, Ryan JF, Shooshtari P, Mathison AJ, Dusetti N, Urrutia R, Lomberk G, Pin CL. Jaune-Pons E, et al. Among authors: martin mb. JCI Insight. 2024 Dec 31:e173746. doi: 10.1172/jci.insight.173746. Online ahead of print. JCI Insight. 2024. PMID: 39739419 Free article.
12,842 results
You have reached the last available page of results. Please see the User Guide for more information.